Dean Irwin Net Worth

The estimated Net Worth of Dean Irwin is at least $85.7 Thousand dollars as of 4 December 2019. Dean Irwin owns over 32,450 units of Catheter Precision stock worth over $32,507 and over the last 5 years Dean sold RMED stock worth over $53,218.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dean Irwin RMED stock SEC Form 4 insiders trading

Dean has made over 1 trades of the Catheter Precision stock since 2019, according to the Form 4 filled with the SEC. Most recently Dean sold 32,450 units of RMED stock worth $53,218 on 4 December 2019.

The largest trade Dean's ever made was selling 32,450 units of Catheter Precision stock on 4 December 2019 worth over $53,218. On average, Dean trades about 32,450 units every 0 days since 2019. As of 4 December 2019 Dean still owns at least 55,097 units of Catheter Precision stock.

You can see the complete history of Dean Irwin stock trades at the bottom of the page.

What's Dean Irwin's mailing address?

Dean's mailing address filed with the SEC is C/O PHIL TENSER, 12520 HIGH BLUFF DRIVE SUITE 240, SAN DIEGO, CA, 92130.

Insiders trading at Catheter Precision

Over the last 6 years, insiders at Catheter Precision have traded over $709,539 worth of Catheter Precision stock and bought 199,373 units worth $197,741 . The most active insiders traders include Jeffrey J Kraws, Jonathan Will Mc Guire, and Dean Burstein Melissa Dean .... On average, Catheter Precision executives and independent directors trade stock every 34 days with the average trade being worth of $12,983. The most recent stock trade was executed by Andrew C. Jackson on 20 November 2021, trading 2,684 units of RMED stock currently worth $7,032.

What does Catheter Precision do?

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of

Complete history of Dean Irwin stock trades at Catheter Precision

Catheter Precision executives and stock owners

Catheter Precision executives and other stock owners filed with the SEC include:

• Jonathan Will McGuire,
  CEO & Director
• Andrew C. Jackson,
  Chief Financial Officer
• Brian D. Conn,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Al Memmolo B.S. MBA,
  Sr. VP of Clinical, Quality & Regulatory Affairs
• Maria Villanueva,
  VP & Compliance Officer
• Tiah Reppas,
  VP, Chief Accounting Officer & Corp. Controller
• James Joseph Caruso,
  
• Dean Dean Irwin & Melissa B...,
  See Remarks
• Joan Stafslien,
  Director
• Martin Martin Burstein Livi...,
  
• William R Enquist,
  Director
• Maurice Buchbinder,
  Director
• Daniel Horwood,
  General Counsel
• Richard Jr Mejia,
  Director
• Martin J Colombatto,
  Director
• Mark E Saad,
  Director
• Dean Burstein Melissa Dean ...,
  
• Thomas G Fogarty,
  See Remarks
• Jeffrey J Kraws,
  Co-President
• David A Jenkins,
  Ex. Chairman of the Board
• Andrew C. Jackson,
  CFO
• Dean Irwin,
  10% owner
• Susanne Meline,
  
• Jonathan Will Mc Guire,
  CEO & Secretary